Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
alosetron · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| alosetron | DRUG | - |
Inclusion Criteria: * Diagnosed with severe diarrhea-predominant Irritable Bowel Syndrome (IBS). * Failed conventional therapy. * Willing to make daily calls on a touch-tone telephone. Exclusion criteria: * History of or current chronic or severe constipation. * Bloody diarrhea, abdominal pain wi...
Alosetron is an investigational small molecule being developed for irritable colon, specifically for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have failed conventional therapy. It is in Phase 3 clinical development and has not been approved by the FDA.
Alosetron is being developed by GSK plc, which trades under the ticker GSK. The company is conducting Phase 3 clinical trials for the drug in the gastrointestinal therapeutic area.
Alosetron is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 3 trials have been completed, both in women with severe diarrhea-predominant irritable bowel syndrome.
Alosetron has two completed Phase 3 trials: NCT00067457 and NCT00067561. Both enrolled women with severe diarrhea-predominant irritable bowel syndrome who had failed conventional therapy, with a combined enrollment of 1,402 participants across the United States and Australia.
Alosetron is a small molecule drug. Its specific molecular target has not been disclosed in the available clinical trial information, so its mechanism of action is not described here.